eToro Pick Healthcare Market Movers: $ABBV $ABT $AMGN

The Market Signal was created as a platform to help investors, if you own (NYSE:ABBV), (NYSE:ABT) or (NASDAQ:AMGN) and want to join the fastest growing community of investors on the web then sign up to the link below. Members get free access to the best investment tools in the world. Start trading like a pro today. This is a limited time offer so click the link below NOW.

(Click link above or copy, paste and hit enter in your browser for your report)

AbbVie Inks Harvard Research Pact

(Click link above or copy, paste and hit enter in your browser for your report)

AbbVie Inc. (NYSE:ABBV) has been on a roll ever since it emerged as one of the companies working on a potential COVID-19 vaccine. The stock has rallied by more than 20% as investors remain bullish about its robust product pipeline. Likewise, it does not come as a surprise that the stock boasts of a 100% buying sentiment on eToro.

With a market cap of more than 160 billion, the company is already looking into the future. The drug maker has already inked a strategic partnership with Harvard University for the development of drugs for the next viruses. The drug maker is to pump $30 million into the partnership over the next three years in addition to providing 'in-kind support'.

The Harvard pact comes at a time when the company is facing pressure from the house committee over pricing strategies involving its lead drug Humira Imbruvica.

Abbott Laboratories Bullish After $5 COVID-19 Test Kit Milestone

(Click link above or copy, paste and hit enter in your browser for your report)

Abbott Laboratories (NYSE:ABT) is flirting with record highs amid renewed and strengthened investor confidence about its long-term prospects. A 100% buying sentiment on eToro comes on the company securing regulatory approval for its $5 rapid test for COVID-19.

With a market cap of more than $190 billion, Abbott Laboratories has presented a game-changing test kit for the coronavirus. With the test kit getting FDA approval, the company is in for a huge payday, which explains why the stock is powering high.

In addition, the company has secured regulatory approval for the use of it's once a day formulation Ivabradine for the treatment of chronic heart failure in India. The company plans to launch the treatment in the Indian market in the next few weeks.

Amgen Reports Positive Data On Cholesterol Cutting Drug

(Click link above or copy, paste and hit enter in your browser for your report)

Amgen, Inc. (NASDAQ:AMGN) upward momentum continues to gather pace as depicted by a 100% buying sentiment on eToro. The stock is already flirting with record highs after the company announced positive data as part of phase 3 study of Repatha in the treatment of pediatric patients with heterozygous Familial.

The trial results show that the Repatha can lower lipoprotein cholesterol in combination with other lipid-lowering therapies. The $150 billion market company hopes to gain regulatory approval for the drug to flex its muscles in the multi-billion cholesterol-cutting market. The company is especially looking to expand Repatha use from adult patient use to adolescent patients.

Please email or contact us for any edits or errors relating to this stock market news.

If you would like information on using our press release distribution service to help investors with the best stocks to buy and how to create your own stock portfolio. We cover the US Stock Market, Canadian Stock Market, the Australian Stock Market, and other Stock Market news.

We will get back to you within 24 hours.


comtex tracking


Is there a problem with this press release? Contact the source provider Comtex at